疏肝祛瘀合剂的制备及临床观察

目的研制疏肝祛瘀合剂(SGQM),建立质量标准,观察其疗效。方法配制疏肝祛瘀合剂,选择患者进行治疗,观察临床疗效。结果该制剂设计合理,制备工艺简单,疗效确切。治疗组55例,总有效率89.3%;对照组40例,总有效率66%,治疗组疗效优于对照组(P<0.05)。结论疏肝祛瘀合剂制备简单,质量可控,疗效满意。     

降酶退黄合剂的制备及临床应用

目的研制降酶退黄合剂(JMTH),建立质量标准,观察其疗效。方法配制降酶退黄合剂,选择患者进行治疗,观察临床疗效。结果该制剂设计合理, 制备工艺简单,疗效确切。治疗组80例,总有效率85%;对照组60例,总有效率65%,治疗组疗效优于对照组(P<0.05)。结论降酶退黄合剂制备简单, 质量可控,疗效满意。     

红伤丸的制备和临床应用

目的 制备红伤丸并验证其临床疗效.方法 根据药物组成设计制备工艺,采用薄层色谱法进行定性鉴别,设治疗组、对照组进行疗效观察.结果 制剂制备工艺简便可行,质量可控.治疗组(n=163)总有效率为97.55%,对照组(n=133)总有效率为89.47%.结论 红伤丸制备工艺合理,质量稳定.临床疗效显著.     

青梅散的制备与临床应用

目的研制青梅散,观察其临床疗效。方法制定制备工艺,质量标准。采用随机对照法,选择120例疱疹性口炎、鹅口疮患者,随机分成治疗组与对照组。治疗组60例用本院自制制剂青梅散治疗,对照组60例用锡类散治疗。结果治疗组总有效率为96.67%,对照组总有效率为85.00%,两组结果有显著性差异(P<0.01)。结论该制剂处方设计合理,制备工艺简便,质量可控,临床疗效显著,值得推广。     

滋肾宁心胶囊的制备及临床应用

目的：研究滋肾宁心胶囊的制备工艺、质量标准及临床应用。方法：部分药材煎煮浓缩、部分粉碎混合制备胶囊，建立质量控制方法，观察对更年期综合征的疗效。结果：治疗组总有效率为93．9％，对照组总有效率为69．8％。结论：该制剂质量可控，疗效可靠，服用方便。     

复方阴道炎栓的制备及临床应用

目的:探讨复方阴道炎栓的制备及质量控制,观察其治疗阴道炎尤其是老年性阴道炎的疗效。方法:以氯霉素、己烯雌酚为主药,明胶甘油为基质制成栓剂。采用HPLC法测定氯霉素和己烯雌酚的含量。结果:治疗组和对照组的总有效率分别为87.5%和70.4%(P<0.05)。结论:该制剂制备方法简单、质量可控、疗效确切。     

复方氟康唑凝胶剂的制备与临床应用

目的制备复方氟康唑凝胶剂,观察临床疗效。方法采用分光光度法建立了该制剂的质量控制标准。结果治疗表皮真菌感染总有效率97.30%。结论该制剂性质稳定,质量可控,疗效确切。     

牛黄益智胶囊的制备及临床应用

目的探讨牛黄益智胶囊的制备工艺、质量标准及临床应用。方法将处方中部分药材煎煮浓缩、其他药材粉碎混合后制备成胶囊剂，并观察其对脑动脉硬化症的临床疗效。结果该制剂制备方法简便；治疗组总有效率为76．67％，对照组总有效率为56．67％，差异显著（P〈0．05）。结论该制剂质量可控，疗效可靠，服用方便。     

咳喘宁糖浆的质量控制及疗效观察

目的制备咳喘宁糖浆,建立质量标准,并观察其临床疗效。方法采用薄层色谱法对制剂中的鱼腥草、麻黄、甘草进行定性鉴别。采用高效液相色谱法对制剂中的盐酸麻黄碱进行含量测定。将260例咳喘患者随机分为治疗组和对照组,每组130例。治疗组口服咳喘宁糖浆,对照组口服急支糖浆。结果治疗组总有效率(96.8%)高于对照组(73.5%),差异有统计学意义(P<0.01)。结论该制剂制备工艺简单,质量可控,临床疗效较好。     

鱼腥草滴眼液的制备及临床应用

目的建立鱼腥草滴眼液的制备及质量控制方法,并观察其临床疗效.方法用水蒸气蒸馏法制备滴眼液,用薄层色谱法进行鉴别;设治疗组、对照组观察疗效.结果治疗组86例,总有效率为96.5%;对照组86例,总有效率为81.3%.结论制备工艺合理,操作方法简便,药物质量可控,临床疗效确切.     

Degraded and undegraded carrageenans and experimental gastric and duodenal ulceration

The prevention of histamine-induced gastric and duodenal ulceration in the guinea-pig has been examined using a series of undegraded and degraded carrageenans. Undegraded carrageenans were active at lower doses than degraded carrageenans. The high viscosity of the undegraded carrageenans in solution prevented their use in larger doses. Degradation of carrageenan without serious loss of sulphate, gives a product which allows the dose to be increased to an extent that its effect more than offsets the slight loss in activity caused by the degradation. No single feature of carrageenan structure can be related to anti-ulcer activity although degradation, and hence reduction of molecular size, generally reduces activity. Sulphate contents over 30% have little apparent effect on activity; κ-carrageenans were not consistently different in anti-ulcer activity from Λ-carrageenans. This contrasts with the antipeptic activity of carrageenans where κ-carrageenans are less active than their Λ-counter-parts. As with antipeptic activity, the degree of anti-ulcer activity is probably determined by a combination of structural features which includes molecular size and polyanionic properties.     

Affective and Anxiety Disorders and Alcohol and Drug Dependence:

Depression and anxiety frequently coexist in patients with substance use disorders. This clinically-oriented article examiens the relationship between these conditions and emphasizes data showing that substances of abuse can cause signs and symptoms of both depression and anxiety. These substance-related syndromes appear to have a different course and prognosis than uncomplicated, independent anxiety and major depressive disorders, and clinicians should consider the role of alcohol and other drugs in all patients presenting with these complaints. The authors will also outline an approach for diagnosing and managing patients with the combination of a substance use and depressive or anxiety disorder.     

Alcohol and Substance Use and Abuse in Women and Children

No abstract available for this article.     

Glucosidase and fucosidase inhibitors and Advances in nucleosides and nucleotides.

The American Chemical Society Symposium "Glucosidase and fucosidase inhibitors" took place on 1 April 1998 and was organized by Professors Zbigniew J Witczak (UConn, School of Pharmacy, CT, USA), Kuniaki Tatsuta (Waseda University, Tokyo, Japan) and Waldemar Priebe, MD (Anderson Cancer Center, University of Texas, USA). Professor Witczak provided introductory remarks including the status of existing glucosidase inhibitors, and chaired the morning session, which consisted of six lectures. The symposium was well received, and was particularly attractive for those interested in networking, as attendance was about sixty. In addition, some participants and attendees presented posters on the subject during the regular poster session organized by the Division of Carbohydrate Chemistry.